BioSpace News Archive

Biotech Bay

Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) announced today that the U.S. Food and Drug Administration (FDA) has provided clearance of its Investigational New Drug (IND) application to initiate clinical testing of TN-201.

January 9, 2023
·
10 min read
Business

ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells

New therapies targeting oncogenic mutations in proteins such as RAS and EGFR hold great promise for people fighting cancer.

January 9, 2023
·
5 min read
Business

PacBio and the University of Tokyo Announce Bioinformatics Applications Collaboration

PacBio today announced a collaboration with the University of Tokyo , Graduate School of Medicine to study the use of long-read sequencing and novel bioinformatics methods in the hopes of better understanding the genetic causes of certain rare diseases in individuals and cohorts within the Japanese population.

January 9, 2023
·
3 min read
Genetown

Syros Announces Clinical Updates and 2023 Strategic Priorities

Syros Pharmaceuticals today provided an update on its clinical development programs and outlined its strategic priorities for 2023.

January 9, 2023
·
9 min read
Business

STAAR Surgical Reports Preliminary Sales for Fourth Quarter and Fiscal 2022

STAAR Surgical Company today reported preliminary sales for the fourth quarter and fiscal year ended December 30, 2022.

January 9, 2023
·
5 min read
Biotech Beach

Neuralace Medical Announces First Patients Enrolled in the AT-PDN Study Evaluating Axon Therapy® for the Treatment of Painful Diabetic Neuropathy

Neuralace Medical, Inc., a commercial-stage medical technology company focused on innovative, non-invasive solutions for treatment of chronic neuropathic pain, is announcing the commencement and first patients enrolled in the Axon Therapy and Painful Diabetic Neuropathy (AT-PDN) study.

January 9, 2023
·
2 min read
Genetown

Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today outlined anticipated 2023 milestones ahead of its participation at the 41st Annual J.P. Morgan Healthcare Conference.

January 9, 2023
·
7 min read
Business

Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement

Avantor, Inc. today announced that it has entered into a multi-year supply and services agreement with Catalent, Inc.

January 9, 2023
·
3 min read
Drug Development

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

IGM Biosciences, Inc. today announced an update on its clinical development program for IGM-8444, a novel multivalent DR5 agonist, and announced plans for a new randomized combination trial in patients with metastatic colorectal cancer.

January 9, 2023
·
7 min read
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase

SAB Biotherapeutics announced today that Alexandra Kropotova, MD, Executive Vice President and Chief Medical Officer, will deliver a presentation at the Biotech Showcase in San Francisco on Tuesday, Jan. 10 at 2:30 p.m. PST.

January 9, 2023
·
4 min read